HQL seeks to partner its programs, enabling HQL to focus on its competitive advantage in drug discovery.
Protein–protein interactions (PPIs) are central to most biological processes, and represent a large and attractive class of targets for therapeutic intervention. These targets cover a broad range of therapeutic areas with high unmet medical need, and HQL is currently pursing two PPI inhibitor programs in the field of oncology.
Both projects are aimed at apoptosis-regulating pathways.
Bcl-2 family of proteins
Many cancer cells overexpress at least one of the anti-apoptotic members of this family, rendering them resistant to chemotherapeutic agents. Therefore these proteins are important targets for the development of new anti-cancer drugs.
IAP family of proteins
A second major control point in the execution of apoptosis. . IAP proteins (Inhibitors of Apoptotic Proteins), as their name implies, confer protection from cell death. Overexpression of IAPs has also been documented in various cancer cells.
A natural IAP inhibitor, SMAC, promotes apoptosis. Small molecule mimetics of SMAC can potentially promote apoptosis. of cancer cells overexpressing both IAPs and Bcl-2 family anti-apoptotic proteins.
PCSK9 - Plays a critical role in LDLR degradation.
Inhibition of PCSK9 leads to increase in LDLR and concomitant decrease in circulating LDL cholesterol.
In the U.S. 63 million people (20%) have an elevated LDLc.
>60% do not reach LDLc lowering goal with statins.